ArticleFrontiers in immunology2018
Inflammation-Induced Adverse Pregnancy and Neonatal Outcomes Can Be Improved by the Immunomodulatory Peptide Exendin-4.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Evaluation of Maternal Inflammatory Biomarkers in Preterm Prelabor Rupture of Membranes: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence.Frontiers in endocrinology · 2023Pooled it
- Cellular immune responses in amniotic fluid of women with preterm labor and intra-amniotic infection or intra-amniotic inflammation.American journal of reproductive immunology (New York, N.Y. : 1989) · 2019Trial
- Fetal T Cell Activation in the Amniotic Cavity during Preterm Labor: A Potential Mechanism for a Subset of Idiopathic Preterm Birth.Journal of immunology (Baltimore, Md. : 1950) · 2019Trial
- Effector and Activated T Cells Induce Preterm Labor and Birth That Is Prevented by Treatment with Progesterone.Journal of immunology (Baltimore, Md. : 1950) · 2019Trial
- Impact of GLP-1 and GLP-1/GIP receptor agonists before, during, and after pregnancy: a narrative review.Diabetology & metabolic syndrome · 2026Review
- GLP-1 Receptor Agonists in Reproductive Medicine: A Narrative Review and Investigational Pilot Survey of Patient Perspectives in Academic Reproductive Endocrinology.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- Reconceptualizing chorioamnionitis as an immune-mediated inflammatory disorder at the maternal-fetal interface.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Perinatal Semaglutide Treatment Improves Maternal Health and Mitigates Offspring Metabolic Dysfunction in a Mouse Model of Maternal Obesity.bioRxiv : the preprint server for biology · 2026Article
- Characteristics, Epigenetics, and Management of Non-Infectious Preterm Birth-Sterile Intrauterine Inflammation and Idiopathic Preterm Birth.Life (Basel, Switzerland) · 2026Review
- Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes: a Danish nationwide cohort study.Human reproduction open · 2026Article
- Incretin receptor agonism during pregnancy: implications for mother and baby.Clinical science (London, England : 1979) · 2025Review
- Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review.Archives of gynecology and obstetrics · 2025Review
- Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- Blockade of IL-6R prevents preterm birth and adverse neonatal outcomes.EBioMedicine · 2023Article
- The MNRR1 activator nitazoxanide abrogates lipopolysaccharide-induced preterm birth in mice.Placenta · 2023Article
- A key role for NLRP3 signaling in preterm labor and birth driven by the alarmin S100B.Translational research : the journal of laboratory and clinical medicine · 2023Article
- Impact of prenatal COVID-19 vaccination on delivery and neonatal outcomes: Results from a New York City cohort.Vaccine · 2023Article
- Benzo(a)pyrene induced adverse pregnancy outcomes by affecting the expression of IL-18 and IL-1RN in placenta.Heliyon · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
Preterm birth is the leading cause of neonatal morbidity and mortality worldwide. Inflammation is causally linked to preterm birth; therefore, finding an intervention that dampens maternal and fetal inflammatory responses may provide a new strategy to prevent adverse pregnancy and neonatal outcomes. Using animal models of systemic maternal inflammation [intraperitoneal injection of lipopolysaccharide (LPS)] and fetal inflammation (intra-amniotic administration of LPS), we found that (1) systemic inflammation induced adverse pregnancy and neonatal outcomes by causing a severe maternal cytokine storm and a mild fetal cytokine response; (2) fetal inflammation induced adverse pregnancy and neonatal outcomes by causing a mild maternal cytokine response and a severe fetal cytokine storm; (3) exendin-4 (Ex4) treatment of dams with systemic inflammation or fetal inflammation improved adverse pregnancy outcomes by modestly reducing the rate of preterm birth; (4) Ex4 treatment of dams with systemic, but not local, inflammation considerably improved neonatal outcomes, and such neonates continued to thrive; (5) systemic inflammation facilitated the diffusion of Ex4 through the uterus and the maternal-fetal interface; (6) neonates born to Ex4-treated dams with systemic inflammation displayed a similar cytokine profile to healthy control neonates; and (7) treatment with Ex4 had immunomodulatory effects by inducing an M2 macrophage polarization and increasing anti-inflammatory neutrophils, as well as suppressing the expansion of CD8+ regulatory T cells, in neonates born to dams with systemic inflammation. Collectively, these results provide evidence that dampening maternal systemic inflammation through novel interventions, such as Ex4, can improve the quality of life for neonates born to women with this clinical condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.